Related Experiment Videos
Chronotherapeutics: are there meaningful differences among antihypertensive drugs?
L Poirier1, J Lefebvre, Y Lacourciere
1Unité de recherche sur l'hypertension, CHUQ pavillon CHUL (S-122), 2705 boul. Laurier, Ste-Foy, Québec Canada G1V 4G2.
Insights
Chronotherapy optimizes drug timing for cardiovascular events in hypertensive patients. This approach, using circadian rhythm knowledge, aims to reduce illness and death by enhancing medication effectiveness.
Area of Science:
- Chronopharmacology
- Cardiovascular Medicine
- Hypertension Management
Background:
- Growing evidence links biological rhythms to cardiovascular event incidence.
- Many treated hypertensive patients experience cardiovascular complications.
- Circadian rhythm influences drug efficacy and potential side effects.
Purpose of the Study:
- To review the science of chronopharmacology in managing hypertension.
- To evaluate the role of drug timing in cardiovascular event prevention.
- To assess novel chronotherapeutic agents and conventional drugs.
Main Methods:
- Review of clinical studies on chronopharmacology.
- Analysis of conventional antihypertensive agents administered at different circadian times.
- Evaluation of new chronotherapeutic agents, including controlled onset extended release (COER)-verapamil.
Main Results:
- Chronotherapy demonstrates potential for improving cardiovascular outcomes.
- Specific drug administration times can enhance antihypertensive efficacy.
- Controlled onset extended release (COER)-verapamil shows promise as a chronotherapeutic agent.
Conclusions:
- Chronotherapy is a valuable approach for reducing morbidity and mortality in hypertensive patients.
- Rigorous evaluation of antihypertensive agents' efficacy and duration is crucial for 24-hour blood pressure control.
- Optimizing drug timing based on circadian rhythms can enhance treatment effectiveness.
Abstract:
In the past decade, many publications have dealt with the possible relationship between biological rhythms and the incidence of cardiovascular events. A high proportion of treated hypertensive patients have cardiovascular complications, and chronotherapy, which permits the use of drugs that are maximally effective at different points in the circadian cycle, may be an interesting and valuable approach to decreasing morbidity and mortality in these patients. This article summarizes current knowledge on the new science of chronopharmacology, as demonstrated in several clinical studies that have used conventional agents administered at various points in the circadian cycle as well as new chronotherapeutic agents, such as controlled onset extended release (COER)-verapamil. In addition, emphasis is given to a rigorous evaluation of antihypertensive agents in terms of efficacy and duration of effect to obtain adequate and sustained lowering of blood pressure over the 24-hour period.